Odaily News The market shows that the AI anti-aging project Aubrai launched by Bio Protocol has a market capitalization of over 20 million USD, currently reported at 20.6 million USD. According to previous news, Aubrai is the first BioAgent new launch project on BIO Protocol.

BlockBeats news, on August 27, according to GMGN data, the first BioAgent Launch project Aubrai of Bio Protocol briefly exceeded a market capitalization of 20 million USD after going live on the Base network, but has now fallen back to 9 million USD, with a Trading Volume of 6.4 million USD in 3 hours since launch.

According to Foresight News, Bio Protocol posted on X stating that the AUBRAI Ignition Sale has seen over 1660 users participate, with a subscription rate of 13.8 times, and less than two hours remaining until the end. The official source stated that they are fixing some front-end issues, and if BioXP and BIO in the user's Wallet have been deducted, they will ensure it counts towards this sale.

BlockBeats news, on August 26, Bio Protocol announced that its first BioAgent Launch project Aubrai (AUBRAI) will not have its TGE immediately after the subscription ends, but will start trading 24 hours later, on Wednesday, August 27. According to the official website, Aubrai has been oversubscribed by 11.6 times.

On August 26, the encryption alts generally fell, with only 14 coins currently rising. Strong coins such as BIO, CRV, MEME, and LDO saw significant declines, with the highest drop reaching 16.84%.

On August 24, it was reported that Whale 0xe0ba deposited 12 million BIO (worth 3.79 million USD) into Binance, having previously received 4.8 million BIO from an unlocked Wallet. Five months ago, he withdrew 15 million BIO from Binance, currently showing a profit of 3.72 million USD.

BlockBeats news, on August 22, according to HTX market data, BIO briefly touched 0.21 USD, currently quoted at 0.2035 USD, with a 24-hour rise of over 37%. The DeSci protocol Bio Protocol recently launched a token launch platform, with the first project being Aubrai. Users can obtain issuance allocation by staking BioXP, and investing in BIO allows them to receive tokens, with the final allocation depending on the staked BioXP share. The sales time for the first BioAgent Launch project Aubrai will last for 24

PANews August 21 news, according to TK Research analysis, $BIO Token is steadily rising in the DeSci field, with the current total Lock-up Position (TVL) of the Bio Protocol being approximately 9 million USD. Among this, about 70% is short-term lock-up (1 to 4 weeks), about 30% is medium to long-term lock-up, and 15.1% is locked for the longest period of 104 weeks. Analysis suggests that the continuous rise of the medium to long-term Lock-up Position ratio may drive up the Token price, while the high proportion of short-term positions may bring certain selling pressure. If the medium to long-term Lock-up Position ratio further increases, $BIO may welcome a new round of price rise.

Gate News Bot news, on August 21, according to CoinMarketCap data, as of the time of writing, BIO (Bio Protocol) is currently priced at 0.15 USD, with a rise of 22.44% in the last 24 hours, reaching a high of 0.17 USD and a low of 0.10 USD. The current market capitalization is approximately 250 million USD, an increase of 45.8 million USD compared to yesterday. Bio Protocol is a new financial layer for DeSci (decentralized science) aimed at accelerating the commercialization of the best scientific achievements. The protocol allows anyone to fund, develop, and manage tokenized scientific innovations from universities, companies, and researchers around the world. The Bio ecosystem is driving a series of decentralized science projects focused on specific therapeutic areas, including longevity research, women's health, psychopharmacology, synthetic biology, and more. Recent important news about BIO

BlockBeats news, on August 21, the DeSci protocol Bio Protocol announced the launch of its first BioAgent Launch project Aubrai, with sales lasting for 24 hours. During this period, users can stake BioXP and invest in BIO tokens to participate. AUBRAI tokens will be immediately available for market trading after the sale ends, and the project launch time will be announced later. According to HTX market information, possibly influenced by the recent increase in use cases, BIO briefly surpassed $0.17 today, currently priced at $0.1421, with a 24-hour rise of 9%.

PANews reported on August 18 that according to CryptoQuant data, Binance held a leading position in the spot trading volume of new tokens in 2025, with a cumulative trading volume of $133 billion, accounting for a market share of 34%. In the past month, its daily trading volume of new tokens peaked at $1.1 billion, reaching a peak on July 10, accounting for a market share of 54%. HTX, Bybit, and MEXC followed closely, recording trading volumes of $38 billion, $35 billion, and $34 billion, respectively. The statistics include exchanges that listed 19 to 31 new tokens this year, with popular tokens including BIO, AIXBT, and CGPT.

Gate News Bot news, on August 18, according to CoinMarketCap data, as of the time of writing, BIO (Bio Protocol) is currently priced at $0.13, with a rise of 31.53% in the last 24 hours, reaching a high of $0.15 and a low of $0.10. The current market capitalization is approximately $220 million, an increase of $52.7 million compared to yesterday. Bio Protocol is a new financial layer in the field of DeSci (decentralized science) aimed at accelerating the commercialization of quality scientific projects. The protocol allows anyone to fund, develop, and manage tokenized scientific innovations from universities, companies, and researchers around the world. Bio Protocol supports promising research projects through low-cap crowdfunding sales and rises as community attention and scientific progress increase. Important news about BIO recently: 1️⃣

Gate News Bot news, on August 12, according to CoinMarketCap data, as of the time of writing, BIO (Bio Protocol) is currently priced at 0.13 USD, with a rise of 14.46% in the last 24 hours, reaching a high of 0.14 USD and a low of 0.06 USD. The current market capitalization is approximately 215 million USD, an increase of 27.2 million USD compared to yesterday. Bio Protocol is a new financial layer of DeSci (decentralized science) aimed at accelerating the commercialization of the best scientific achievements. This protocol allows anyone to fund, develop, and manage tokenized scientific innovations from universities, companies, and researchers around the world. The Bio ecosystem is driving biotechnology innovation, accelerating drug development through decentralized financing and coordination, shortening the development cycle from decades to months. Important news about BIO recently: 1️⃣ **Staking Power

Gate News Bot news, on August 08, according to CoinMarketCap data, as of the time of writing, BIO (Bio Protocol) is currently priced at 0.09 USD, having risen 48.96% in the last 24 hours, reaching a high of 0.10 USD and a low of 0.05 USD. The current market capitalization is approximately 150 million USD, an increase of 49.4 million USD compared to yesterday. Bio Protocol is a new financial layer of DeSci (Decentralized Science) aimed at accelerating the commercialization of the best scientific achievements. The protocol allows anyone to fund, develop, and manage tokenized scientific innovations from universities, companies, and researchers around the world. Bio Protocol supports promising research through low-capital fundraising and rises with community interest and scientific progress. Important news about BIO recently: 1️⃣ **Bio Prot

Nomura predicts that the mid-term revenue of Kangfang Biotech will increase by 42% to 1.45 billion RMB, which is 3% lower than market expectations. The company's revenue in the second half of the year is expected to be driven by the sales of Ketanserin and Idarubicin, with the full-year net profit forecast raised by 97.2%. The target price is adjusted to HKD 120.64, maintaining a neutral rating.

Jin10 Data reported on July 10 that Sanyuan Biotech announced that shareholder Luxin Capital plans to reduce its holdings in the company by a total of no more than 6 million shares through centralized bidding and block trading methods within 3 months after the 15 trading days from the date of announcement. This represents no more than 3% of the total share capital after excluding shares held in the company's repurchase special securities account. The reason for the reduction is the company's operational development needs, and the reduction price will be determined based on market prices. Luxin Capital is not the company's controlling shareholder or actual controller, and this reduction will not lead to a change in the company's control rights, nor will it have a significant impact on the company's governance structure and ongoing operations.

Jin10 data reported on July 8, TianKang Bio announced that in June 2025, it sold 243,100 live pigs, a year-on-year decrease of 6.14%, but a month-on-month rise of 5.83%; the sales revenue was 342 million yuan, a year-on-year decrease of 19.53%, and a month-on-month decrease of 0.87%. From January to June 2025, the company sold a total of 1,528,200 live pigs, a year-on-year increase of 9.05%; the cumulative sales revenue was 2.244 billion yuan, a year-on-year decrease of 0.27%.

Jin10 data reported on June 25 that Hotgen Biotech announced that shareholder Zhou Xin plans to reduce his holdings of the company's shares by no more than 1.8 million shares through centralized bidding and Block Trading, accounting for 1.9416% of the company's total share capital. As of the announcement date, Zhou Xin holds 6.8066 million shares of the company, accounting for 7.3420% of the total number of shares, with the shares sourced from holdings prior to the company's initial public offering and from capital reserve converted into share capital.

Jin10 data reported on June 19 that Shengnuo Bio announced it expects to achieve a net profit attributable to the owners of the parent company of 77.0275 million yuan to 94.1448 million yuan for the first half of 2025, an increase of 55.2399 million yuan to 72.3571 million yuan compared to the same period last year, representing a year-on-year increase of 253.54% to 332.10%. It is expected that the net profit attributable to the owners of the parent company, after deducting non-recurring gains and losses, will be 77.3464 million yuan to 94.5345 million yuan for the first half of 2025, an increase of 58.2244 million yuan to 75.4125 million yuan compared to the same period last year, representing a year-on-year increase of 304.49% to 394.38%.

Jin10 reported on June 9 that Ripple Bioscience stated on the interactive platform that Chao Bixin has been listed in May this year, and Miao Pu Jing plans to be listed soon.

On June 3, Jin10 reported that Huaxi Bio responded to reporters regarding the dispute over recombinant collagen with Giant Bio, stating that it opposes the name game of "recombinant" collagen, rather than opposing the scientific research and industrial transformation of collagen. The company places more importance on the interaction between HA and collagen in ECM and points out that the credibility of domestic brands should not be based on concept abuse. It hopes the industry can return to product quality issues and seek solutions.

Jin10 data reported on May 29, Rongchang Bio announced that the company has successfully allocated and issued a total of 19 million new H shares to no less than six subscribers at a placement price of HK$42.44 per share on May 29, 2025, accounting for approximately 9.11% of the total issued H shares after the placement and issuance, and about 3.37% of the total issued shares. The total amount raised from the placement is approximately HK$806 million, and the net amount received by the company from the placement (after deducting the Commission and estimated expenses) is approximately HK$796 million.

According to the Gate News bot, data from Tokenomist shows that several crypto asset projects will experience large-scale unlocks in the next 7 days. Among them, projects with a single unlock amount exceeding $5 million include SUI, BIO, OP, KMNO, ZETA, ALT, VENOM, REZ, and DYDX. At the same time, projects such as SOL, WLD, TIA, DOGE, TAO, AVAX, SUI, DOT, IP, MORPHO, NEAR, ETHFI, JTO, and FIL will undergo linear unlocks, with daily unlock amounts exceeding $1 million. The total value of this unlock reaches $549 million.

Jin10 data reported on May 23 that Nomura's research report indicated that the placement of new H shares by Rongchang Bio (09995.HK) is favourable information for the group's financial situation. The bank believes that the current strong sentiment in the market towards biotechnology companies provides a good issuance opportunity for the group, while the HK$800 million raised from the placement will strengthen the group's limited cash position. The bank also believes that the prospects for asset outsourcing licensing have become brighter, thus raising the group's target price by 190.8%, from HK$16.37 to HK$47.6. The rating remains "Neutral."

Bio Protocol has proposed the BIOPSY proposal to postpone the unlocking of team and advisor tokens until November 2025 and change to a linear unlocking every 6 months, aiming to rearrange the token vesting plan.

According to BlockBeats news, on May 16, Nansen stated on social media that in the past 24 hours, the tokens with the highest net inflow of Smart Money were: · SYRUP: 1.12 million USD · BIO: 582,900 USD · GOONC: 304,800 USD

The DeSci zone Token rebounded on May 14, with prices of RIF, URO, RSC, BIO, and VITA rising by 41.8%, 36.9%, 20.6%, 18.5%, and 17.4%, respectively.

The celebrity coin GOONC issued by KOL Pata van Goon on the meme issuance platform X has seen its market capitalization exceed 20 million USD within 4 hours, now standing at 22 million USD, with a trading volume of 25.6 million USD. According to the information on his page, a16z co-founder Marc Andreessen follows this account, and his bio shows "applied @openai". Users are reminded that meme coins have no actual use cases and are subject to significant price fluctuations, so caution is advised.

On April 30, Jin10 reported that Bio Company stated on the interactive platform that the company currently has no products exported to the United States, and the additional tariffs have no impact on the company's existing business.

Jin10 data April 15 news, Saito Bio stated on the interactive platform that revenue directly from the U.S. market accounted for less than 3% of the company's total revenue in 2024. The company will actively expand other overseas markets, flexibly adjust its business strategy, and move forward steadily.

Jin10 reported on April 6 that Shengda Bio announced that its major shareholder, Tiantai Wanjian Investment Development Center (Limited Partnership), is implementing the previously disclosed share reduction plan. The company will reduce its shares by 2,328,400 through block trading and bidding, accounting for approximately 1.36% of the company's total share capital. This change in equity does not trigger a mandatory acquisition and will not result in changes to the company's controlling shareholder or actual controller.

Bio Protocol has launched its first major protocol upgrade, Bio V1, on Solana and Base, introducing features such as Launchpad, Liquidity Engine, and BioAgents, simplifying the biotechnology financing process. BIO Token holders can decide on the project's launch and development direction, and enjoy early allocation priority. By investing in BIO, discounts on BioDAO tokens can be obtained. Bio V1 aims to facilitate early biotechnology development.

PANews April 1 news, according to The Block, the decentralized research platform Bio Protocol has launched a V1 version upgrade, based on Base and Solana, with core features including the BioDAO Launchpad, AI-driven BioAgents, and a new DAO milestone mechanism. The new system has transitioned from the original screening accelerator to a fully on-chain project declaration and financing process, expanding the practical utility of BIO Token in governance, financing, and services, promoting the democratization of research in the DeSci field.

Jin10 data reported on March 27 that Nuotai Bio announced that it expects a net profit attributable to the parent company's owners in the first quarter of 2025 to be between 130 million and 170 million yuan, an increase of 63.6732 million to 103.6732 million yuan compared to the same period last year, representing a year-on-year increase of 96% to 156%. The performance growth is mainly due to the significant increase in sales revenue from the company's peptide raw materials and other products.

BlockBeats news, on March 25, according to GMGN market data, DeSci zone Tokens are rebounding, among which: BIO is currently priced at $0.1008, with a 24-hour rise of 16.26%; VITA is currently priced at $1.28, with a 24-hour rise of 10.2%; YNE is currently priced at $0.0188, with a 24-hour rise of 15.7%.

The Bio Protocol of DeSci project plans to create a Decentralization BioAgents team in 2025, using new biotechnological tools to accomplish scientific missions and integrate tokenomics. Each BioDAO will be equipped with coordinating agents to help scientists focus on research. BIOToken is key to incentivizing and managing the rise of the team, and external partner fees will be destroyed.

Rongchang Biotech responded: The decrease in expected value due to the non-promotion of the indication of Vedolizumab (RC48) led to a devaluation of 200 million US dollars by the partner Pfizer. The overseas rights of this drug were authorized to ADCleading company Seagen in August 2021 and later acquired by Pfizer. Currently, Pfizer is promoting the indication of Vedolizumab for urothelial carcinoma overseas.

VitaDAO will airdrop 2 million BIO tokens to VITA and VitaDAO IPTholders, with 50% available immediately and the remaining 50% distributed according to a 1-year linear unlocking schedule. This proposal is an improvement on VDP-161, and Solana VITAholders will be eligible participants.

Odaily Planet Daily News. Donald Trump Jr., in his Instagram bio, added "Meme Wars General," which means Meme

Jinshi data news on January 14th, Rejing Biology announced that, according to the preliminary calculation of the finance department, it is expected that the annual operating income in 2024 will be 490 million to 520 million yuan, a decrease of 3.93% to 9.47% compared with the same period last year. It is expected that the net profit attributable to the owners of the parent company in 2024 will be -175 million to -200 million yuan. Compared with the same period last year, there will be a loss. It is expected that the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses in 2024 will be -240 million to -265 million yuan.

Bio Protocol, DeSci AI, and Long COVID Labs are collaborating to accelerate research on the novel coronavirus (Long COVID) using proxy technology. The goal is to identify research errors, potential drug targets, and enhance research data accessibility. Long COVID Labs is auctioning COVID tokens, and the auction will end on January 17th at 23:00.

BlockBeats news, on January 10th, according to the official announcement from Pump Science, the Airdrop of 2.5 million BIO Tokens to RIF and URO holders has begun. The Airdrop distribution is based on 3 Snapshot Nodes in November, December, and January, and holders of all Snapshot Nodes will receive a 2.5 times Airdrop bonus. In addition, each Wallet can receive up to 8000 tokens at most.

PANews January 9th news, the proposal submitted by the VitaDAO community to distribute 6.9 million BIO Tokens to VITA and VITA IPT holder has been rejected. According to the proposal, the allocation plan is to allocate 5.52 million BIO to VITA holders and 1.38 million BIO to VITA.

The VitaDAO's plan to conduct the BIOToken Airdrop to its community has been vetoed. The proposal planned to allocate 6.9 million BIOTokens from the total supply of 21 million for a tiered system Airdrop. 80% (5.52 million) would be distributed to VITA holders, and 20% (1.38 million) would be distributed to VITA IPT holders.